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ABSTRACT
MicroRNAs (miRNAs) are small non-coding RNAs
that mediate gene expression at the post-
transcriptional and translational levels by an imper-
fect binding to target mRNA 30UTR regions. While
the ab-initio computational prediction of miRNA–
mRNA interactions still poses significant chal-
lenges, it is possible to overcome some of its
limitations by carefully integrating into the analysis
the paired expression profiles of miRNAs and
mRNAs. In this work, we show how the choice of a
proper probe annotation for microarray platforms is
an essential requirement to achieve good sensitivity
in the identification of miRNA–mRNA interactions.
We compare the results obtained from the analysis
of the same expression profiles using both gene
and transcript based custom CDFs that we have
developed for a number of different annotations
(ENSEMBL, RefSeq, AceView). In all cases,
transcript-based annotations clearly improve the
effectiveness of data integration and thus provide
a more reliable confirmation of computationally pre-
dicted miRNA–mRNA interactions.
INTRODUCTION
MicroRNAs (miRNAs) are a family of small non-coding
RNAs, derived from hairpin precursors, abundant in
animals, plants and viruses (1–8). miRNAs play central
roles in cell differentiation, in the development of tissues
and organs, in the pathogenesis of human diseases (9,10)
and tumors (11–13). At the molecular level miRNAs influ-
ence the stability and translational efficiency of target
RNA messengers (mRNAs), mainly by an imperfect
binding to their 30UTR regions (14). More than 800
miRNAs have been identified in human and mouse (15);
computational predictions provide even higher figures
(16). Recent works estimate that, on average, each
miRNA can regulate 200 target genes (17–19), suggest-
ing that a wide proportion of mammalian genes and bio-
logical processes respond to miRNA control mechanisms.
The computational prediction of miRNA targets is
extremely challenging due to the lack of a sufficiently
large group of experimentally validated targets to be
used as a robust training set, and of high-throughput
experimental methods for validating results (16). Tools
like miRanda, TargetScan, PicTar, PITA and
RNAhybrid (19–25), though based on different algorithms
and philosophies, all suffer from the limited understanding
of the molecular basis involving miRNA-target pairing,
that probably, in turn, leads to a reduction of their pre-
dictions specificity (26,27). The integration of in-silico pre-
dictions with other genomic data may overcome the limits
of computational predictors and facilitate the identifica-
tion of functional interactions. In particular, the combi-
nation of target predictions with paired miRNA–mRNA
expression profiles has been proposed as an efficient way
to refine results obtained from methods based on
sequences alone.
Although miRNAs may stabilize transcriptional regula-
tion through complex feed-forward and feed-back loops
(28), integrative approaches postulate that miRNAs
down-regulate mRNAs and that the expression profiles
of genuinely interacting miRNA–mRNA pairs are
anti-correlated. The standard integrative approaches
comprise three steps: (i) prediction of miRNA targets
through sequence-based algorithms, (ii) quantification of
target expression levels and (iii) assessment of the
anti-correlation among miRNAs and their predicted
targets. The anti-correlation can be quantified through a
variational Bayesian model (29,30) or by computing a cor-
relation coefficient among miRNA and mRNA expression
signals (31–33).
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Given that miRNA interactions depend on specific
sequences in the 30UTR regions of their targets and that
alternative transcripts of a same gene may differ in such
UTRs, integrative analyses of expression profiles must
take into account the entire length of a transcript. This
has been clearly shown by Legendre and colleagues (34)
who studied 30UTRs containing multiple EST-supported
poly(A) sites, and looking for known miRNA targets and
other phylogenetically conserved motifs, highlighted
that motif-containing and motif-free isoforms were
differentially represented in specific tissues. In addition,
other studies demonstrated that the same miRNA target
prediction algorithm produces significantly different
results when applied to genes/transcripts defined by
distinct annotations: for example, Rajewsky et al. (25)
reported a 20% variability in the predicted regulatory
relationships moving from RefSeq transcripts to UCSC
‘known genes’. Target identification, moreover, was
affected by alternative adenylation and multiple polyA
sites in terminal exons (25,35).
The choice of a transcript-based (TB) approach influ-
ences the analysis right from the quantification of target
expression. It is well known that a considerable fraction of
microarray probes can be (i) entirely mis-assigned (not
associated to any gene/transcript in a recent genome anno-
tation), (ii) non-gene-specific (i.e. matching multiple genes)
or (iii) non-transcript-specific (matching multiple alterna-
tive transcripts of a gene). Several groups have explored
the effects of using alternative microarray annotations to
quantify gene expression (36,37) and proposed the
adoption of custom Chip Definition Files (CDFs)
(38–41). The importance of the annotation increases
when we consider the integration of miRNA and
mRNA expression data because of the role played by
alternative 30UTRs. Unfortunately, the computational
procedures developed so far seem to overlook this aspect
and adopt gene based CDFs to correlate miRNA-target
profiles. The matter is further complicated by the ambig-
uous definition of a gene 30UTR region, which may be
taken as the union of all 30UTRs of its transcripts or as
the longest one (42).
In this work we investigate how different microarray
probe annotations affect the integrative analysis of
miRNA-mRNA expression. The analysis has been per-
formed through a computational pipeline that (i)
re-annotates microarray probes into GB (gene based)
and TB custom CDFs; (ii) predicts miRNA targets
starting from transcripts and miRNA sequences; (iii) inte-
grates miRNA target predictions with paired miRNA–
mRNA expression signals. In particular, we explore the
degree of specificity of miRNA seed pairing to alternative
30UTR splicing variants and then compare the miRNA–
mRNA expression correlation obtained from GB and TB
probe annotations. The entire procedure has been tested
on paired expression data originally collected to investi-
gate the role of perineural invasion pathway (PNI) in
prostate cancer (43). Results clearly show that microarray
probe annotations have a substantial impact on the
integrative analysis and that TB annotations outperform
their GB counterparts.
MATERIALS AND METHODS
We have developed a computational pipeline (Figure 1) to
compare the efficiency of GB and TB annotations in the
integrative analysis of miRNA–mRNA data. Such
pipeline is composed of three major steps: (i)
re-annotation of microarray probes to design GB and
TB custom CDFs; (ii) prediction of miRNA targets
using the sequences of transcripts and miRNAs; (iii) inte-
gration of miRNA target predictions with paired
miRNA–mRNA expression signals.
In the first step we used the sequences of Affymetrix
microarray probes and those of transcripts and genes
derived from several annotations (ENSEMBL, RefSeq,
AceView) to build custom CDFs. We then obtained
miRNA sequences from the mirBase database and used
the miRanda, PITA and PicTar algorithms to predict their
targets (both at the gene and at the transcript level). In the
last step we evaluated gene and transcript expression
profiles, and we integrated each with the corresponding
miRNA expression signals to refine the predicted
miRNA–mRNA interactions.
Transcript sequences and annotations
Transcript sequences and annotations were obtained from
three databases, i.e. ENSEMBL (version 52), RefSeq
(version 33) and AceView (UCSC hg18). Some RefSeq
transcripts were associated to multiple UTRs of different
extension; to remove redundancy, we defined a single
30UTR as the region going from the first base after the
end of the coding sequence to the first annotated polyA
site.
Construction of custom CDFs
GB and TB custom CDFs have been built for a number of
human Affymetrix arrays (i.e. HG95v2, HG133A 2.0,
HG133plus2, and Human Exon 1.0 ST) using the
ENSEMBL, RefSeq and AceView annotations.
Specifically, the custom CDFs were generated (i)
matching gene/transcript sequences with all the probes
of the microarray, (ii) filtering out all non-specific
probes, i.e. those matching more than one gene/transcript,
(iii) grouping probes into meta-probe sets with at least
four entries, and finally, (iv) discarding all those probes
not belonging to any meta-probe set. Details on the
number of specific probes and of recognized genes and
transcripts are reported in Supplementary Table S1.
Prediction of miRNA targets
Human miRNA sequences were obtained from the
miRBase::Sequences repository (version 12). We updated
target predictions using three different algorithms,
characterized by different target identification strategies
(miRanda, PITA and PicTar). We ran miRanda and
PITA over the ENSEMBL, RefSeq and AceView annota-
tions; PicTar target predictions, based on RefSeq
sequences, were downloaded as provided by PicTar devel-
opers since the software is not freely available.
The thresholds for miRanda and PITA were defined
applying the two algorithms to artificial sequences
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generated through a permutational approach, i.e. shuffling
30UTR sequences. miRanda scores were all smaller than
200 when applied to shuffled data, while PITA did not
recognize any target at all. As a result, the threshold
score of miRanda was set to 200 while targets predicted
by PITA were further limited to those with the top 10%
scores.
Integrative analysis of mRNA and miRNA
expression data
We obtained from the GEO database matched mRNA
and miRNA expression data of 57 prostate cancer
samples [GSE7055 (43)] generated using Affymetrix
HGU133A 2.0 microarrays and OSU-CCC MicroRNA
custom arrays, respectively.
Figure 1. Computational pipeline. Detailed scheme of the pipeline implemented for the construction of our custom CDFs and for the miRNA–
mRNA expression profiles integration.
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The Robust Multichip Average model with quantile
normalization and HG133A 2.0 custom-CDFs were used
to generate and normalize mRNA expression signals.
miRNA expression levels were pre-processed using the
approach adopted in the original publication (43). Briefly,
spots having signal/background ratio below a specific
threshold (calculated as the average of blank spots) were
filtered out; each experiment was normalized dividing the
expression values by their corresponding median level;
replicate signals within the array were averaged. This pro-
cedure resulted in a matrix containing the expression levels
of 426 miRNAs, 236 of which were human-specific.
To evaluate the impact of GB and TB annotations on
the integration of miRNA–mRNA expression data, we
used only those probe sets of the HG133A 2.0 GB-CDF
that measured genes having at least one transcript repre-
sented by a probe set in the HG133A 2.0 TB-CDF. In
addition, we filtered out genes having a single transcript
(the choice of the type of annotation does not affect the
quantification of their expression signal). The filtering pro-
cedure resulted in 1715 genes and 1818 transcripts using
ENSEMBL, 621 genes and 746 transcripts with RefSeq
and 12 184 genes and 4599 transcripts considering the
AceView annotation. These genes and transcripts were
then used as targets to predict miRNA-target interactions
with miRanda, PITA and PicTar (the latter is limited to
RefSeq sequences only; see Supplementary Table S2).
We calculated the correlation among all miRNA and
mRNA expression profiles using both parametric
(Pearson) and non-parametric (Spearman) coefficients.
To quantify the impact of different annotations we
defined the delta correlations (c) as the differences
between the correlation levels of a miRNA-gene pair
and all of the corresponding miRNA-transcript pairs.
The significance of the c was assessed comparing the
observed c with c*, the distribution of c calculated
by randomly permuting 100 times the mRNA expression
levels. Specifically, since the maximum absolute value of
c* resulted equal to 0.2, a |c|> 0.2 was considered as
an indication of a significant impact of the type of probe
annotation (GB or TB) on the correlation of miRNA–
mRNA expression data.
Functional enrichment
We calculated the functional enrichment of target genes
obtained through TB and GB approaches using the
hypergeometric distribution (Fisher exact test) and the
GSEA (44,45). The hypergeometric test was performed
in DAVID (46) with KEGG (47) and Biocarta pathways
(EASE score less than 0.1), while we used the Java appli-
cation of the Broad Institute (http://www.broadinstitute.
org/gsea/) for the GSEA.
RESULTS AND DISCUSSIONS
Analysis of 30UTR alternative transcripts
The transcript annotation databases, ENSEMBL (v.52),
AceView (UCSC hg18) and RefSeq (v.33), provided a
total of 54 617, 260 113 and 46 417 transcripts (respec-
tively), resulting in 39 680, 210 003 and 33 518 sequences
with annotated 30UTR regions. The distribution of the
number of transcripts per gene according to ENSEMBL,
RefSeq and AceView showed that a significant fraction of
genes (30% for ENSEMBL, 20% for RefSeq and 29% for
AceView) have at least two alternative transcripts (Figure
2A and Table 1). Moreover, as different transcripts may
share the same 30UTR, transcripts with the same 30UTR
have been considered as putative targets of the same set of
miRNAs. We define a 30UTR equivalence class as a set of
transcripts of a gene sharing exactly the same 30UTR
sequence. A significant fraction of genes (71% for
ENSEMBL, 36% for RefSeq and 94% for AceView) has
two or more equivalence classes (Figure 2B and Table 2);
such variability in the proportions may be ascribed to dif-
ferences in terms of annotations of the human genome
(48). For instance, predicted alternative transcripts with
different 30UTRs are more numerous and longer in
ENSEMBL than in RefSeq. On the contrary AceView,
that has been developed to provide a strictly
cDNA-supported view of the human transcriptome and
to summarize all quality-filtered cDNA data from
GenBank, dbEST and RefSeq, is characterized by a
larger number of alternative transcripts within the same
gene, most of which have different 30UTR sequences
(Figure 2B).
We used the miRanda, PITA and PicTar algorithms to
evaluate the specificity of miRNA target predictions with
respect to 30UTR equivalence classes. We computed for
each putative miRNA-gene pair the percentage of equiva-
lence classes recognized by the miRNA. Figure 2C and D
and Supplementary Figure S2A shows the distribution of
the average percentage of 30UTR equivalence classes per
miRNA over all its putative target genes using miRanda,
PITA and PicTar, respectively. These findings indicate that
the heterogeneity of alternative 30UTRs results in miRNAs
highly specific in their targeting 30UTR equivalence classes.
Indeed, while using ENSEMBL and RefSeq approximately
half of all 30UTR equivalence classes of a protein-coding
gene are recognized by a specific miRNA; with AceView
this quantity drops to <20%, indicating a greater miRNA
specificity.
Considering that 26% of genes have more than one
transcript (taking the average over the three annotation
databases), GB data integration could be deceptive for a
significant proportion of protein-coding genes. Indeed,
71% of ENSEMBL genes with more than one transcript
exhibit more than one 30UTR equivalence class; a GB data
integration would have been ambiguous for at least 18%
of them (9 and 23% for RefSeq and AceView, whose pro-
portions of genes having more than one 30UTR equiva-
lence class are 36 and 94%, respectively). As an example,
the BAIAP2 gene (brain-specific angiogenesis inhibitor-1,
ENSG00000175866, a secretin receptor family member
whose expression is induced by p53) is associated to
three different transcripts which differ in their 30 region
(30CDS and 30UTR) and encode different isoforms of an
insulin receptor tyrosine kinase substrate of the secretin
receptor family (49). Figure 3 shows the alternative tran-
scripts of BAIAP2 that are characterized by the same
50 region and their regulating miRNAs. Among the 95
miRNAs regulating BAIAP2, only 7 (7%) are shared by
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all transcripts, while 45% of them (9% for
ENST00000321300, 36% for ENST00000321280 and
none for ENST00000321238) are transcript-specific. This
evidence supports the hypothesis that using GB instead of
TB annotation for miRNA–mRNA data integration could
lead to misleading results.
Construction of custom CDFs
Several groups have explored the effect of using alternative
microarray annotations to improve the estimation of
expression values. For instance, Dai and colleagues peri-
odically update several custom CDFs for various
Figure 2. The 30UTRs transcript variability. (A) Distribution of the number of transcripts per gene. (B) Distribution of the number of different
30UTRs per gene (hereafter called 30UTR equivalence classes) with at least two alternative transcripts. (C) Distribution of the average number of
30UTR equivalence classes per gene targeted by miRNAs using ENSEMBL, RefSeq and AceView databases with miRanda target prediction algo-
rithm. (D) Distribution of the average number of 30UTR equivalence classes per gene targeted by miRNAs using ENSEMBL, RefSeq and AceView
databases with the PITA target prediction algorithm.
Table 1. Distribution and cumulative distribution of the number of genes with transcript variants according to ENSEMBL (v 52), RefSeq (v.33)
and AceView (UCSC hg18)
Number of transcript
variants within a gene
ENSEMBL RefSeq AceView
Frequency
(%)
Cumulative frequency
(%)
Frequency
(%)
Cumulative frequency
(%)
Frequency
(%)
Cumulative frequency
(%)
1 69.9 69.9 80.4 80.4 70.8 70.8
2 13.7 83.6 13.3 93.7 5.0 75.8
3 7.3 90.9 3.5 97.2 3.1 78.9
4 3.9 94.8 1.4 98.6 2.7 81.6
5 2.0 96.8 0.5 99.1 2.3 83.9
>5 3.2 100 0.9 100 16.1 100
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Affymetrix platforms (38). In their annotation pipeline,
however, probes of a given meta-probe set may match dif-
ferent transcripts. As such transcripts may have different
expression profiles, the use of non-specific probes in the
process of signal quantification could bias the expression
value estimates by increasing expression variability. To
overcome this limitation, we have developed an alternative
annotation scheme and, as suggested by Moll et al. (41),
eliminated all non-specific probes. In particular, we recon-
structed TB custom CDFs for the most commonly used
Affymetrix arrays using ENSEMBL, RefSeq and AceView
sequences. Table 3 and Supplementary Table S1 shows the
details, in terms of number of genes, probes and transcripts
contained in the custom CDF for the HGU133A 2.0
platform based on the three different annotation databases.
Integrative analysis of paired miRNA–mRNA
expression profiles
We have used the computational pipeline of Figure 1 for
the analysis of paired miRNA–mRNA expression data
from 57 prostate cancer samples (43) in order to
evaluate the impact of TB annotations on the identifica-
tion of miRNA targets. The comparative evaluation of
GB and TB approaches focused only on those genes
having at least two alternative transcripts, i.e. on those
cases where the TB annotation should improve data inte-
gration. In particular, we evaluated the distributions of
differences between correlation estimates (c), i.e. the
impact of the annotation adopted for expression signal
quantification (GB or TB), as a function of the algorithm
used for the prediction of miRNA targets (miRanda,
PITA or PicTar) and of the type of correlation
(parametric or non-parametric coefficients). Figure 4A–C
shows the distribution of c using the miRanda algorithm
for the prediction of miRNA targets and similar results
are reported in Supplementary Figures S1A and S2B when
using PITA and PicTar, respectively. c distributions are
centered on zero for all annotation databases and for all
type of correlations, but are interestingly characterized by
strong kurtosis levels (fat distribution tails), suggesting the
Figure 3. Differences between gene and transcript-based annotation approaches. miRNAs regulating the three alternative transcripts of the gene
BAIAP2. Triangles represent transcripts and circles miRNAs. The Venn diagram highlights the fact that only 7% of the 95 miRNAs regulating
BAIAP2 are shared by all transcripts, while 45% of them (9% for ENST00000321300, 36% for ENST00000321280 and none for ENST00000321238)
are transcript-specific.
Table 2. Distribution and cumulative distribution of the number of 30UTR equivalence classes per gene with at least two alternative 30UTRs
according to ENSEMBL (v 52), RefSeq (v.33) and AceView (UCSC hg18)
Number of 30UTRs
within a gene
ENSEMBL RefSeq AceView
Frequency
(%)
Cumulative frequency
(%)
Frequency
(%)
Cumulative frequency
(%)
Frequency
(%)
Cumulative frequency
(%)
1 29.0 29.0 64.0 64.0 6.0 6.0
2 45.7 74.7 30.8 94.8 17.7 23.7
3 15.7 90.4 4.2 99.0 10.8 34.5
4 5.7 96.1 0.9 99.9 9.5 44.0
5 2.5 98.6 0.02 99.92 8.2 52.2
>5 1.4 100 0.08 100 47.8 100
6 Nucleic Acids Research, 2010
presence of feed-forward and -back transcriptional regu-
lation (28). The significance threshold for c has been
assessed through a permutational approach and set
equal to 0.2 (see ‘Materials and methods’ section for
details and Supplementary Figure S3 for the distributions
of delta correlations of real and randomly permuted data).
This threshold allowed us to select those genes/transcripts
whose correlation coefficient with at least one miRNA is
affected by the choice of the annotation (GB or TB).
Specifically, 7% of ENSEMBL and AceView gene/tran-
scripts and 14% of RefSeq ones resulted in delta correla-
tions exceeding the threshold of 0.20 (|c|> 0.2 at a
FDR< 0.1, Supplementary Figure S4). Among this
remaining fraction of interactions, we further considered
only those miRNA–mRNA pairs having the top 1%
anti-correlation coefficients. As expected, the adoption of
GB or TB annotations severely affects the number of
miRNA–mRNA interactions, as well as the number of
relevant miRNAs and target genes involved in putative
interactions (Figure 4D), irrespective of the considered
database. Although the aim of Legendre et al. study (34)
was different from our goal (they do not perform
integrative analysis with microarray data and do not
evaluate the impact that chip annotation has on correla-
tion calculation), their findings on few specific miRNAs
were concordant with our results. For instance, among the
248 most significant anti-correlated mRNA–miRNA pairs
identified using miRanda and ENSEMBL, only 151 (60%)
are shared between GB and TB lists. Forty-eight miRNA–
mRNA pairs, on the other hand, are specific to the GB
and 49 to the TB annotations, respectively. Differences in
the top 200 anti-correlated interactions identified through
Figure 4. miRNA–mRNA correlations. Differences in parametric and non-parametric correlation estimates obtained using transcript and gene-based
annotations, respectively, using ENSEMBL (A), AceView (B) RefSeq (C) sequences and miRanda algorithm. (D) Number of miRNA–mRNA
interactions, miRNAs and target genes involved in the putative 1% most relevant interactions detected using gene- and transcript-based annotations.
Table 3. Number of unique probes covering genes and transcripts for the construction of our custom CDFs for the Affymetrix platform
HG133A 2.0
Platform ID ENSEMBL RefSeq AceView
Number of genes 12 136 12 011 12 184
Number of unique probes covering genes 186 624 185 315 193 901
Number of transcripts 6583 8842 4599
Number of unique probes covering transcripts 86 756 124 420 51 227
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the PITA and miRanda are reported in Supplementary
Figure S1 (panel B).
Figure 5 shows some examples of miRNA–mRNA
interactions together with their GB and TB delta correla-
tions; this highlights the bias introduced by the GB anno-
tation. As an example, all three transcripts of the BAIAP2
are putative targets of miR-328, but the anti-correlation of
expression signals is not significant (e.g. 0.06) using the
GB approach. Using TB annotations, on the other hand,
ENST00000321300 and miR-328 show a significant
negative correlation (e.g. 0.3), whereas expression data
indicate no correlation between ENST00000321280 and
ENST00000321280 and miR-328 (0.02 and 0.03,
respectively).
Enrichment analyses
An optimal approach should identify, among the sup-
ported miRNA–mRNA interactions, a significant propor-
tion of targets and miRNAs with a known role in the
pathological processes under examination. As such, we
verified the functional enrichment of the most significant
anti-correlated mRNA-miRNA pairs among those pre-
dicted by miRanda on the ENSEMBL database and con-
firmed using GB and TB annotations (Figure 4).
Specifically, we performed gene set enrichment analysis
on GB and TB lists of targets and a literature search on
the identified miRNAs. The list of targets obtained
through the TB annotation led to highly enriched meta-
bolic pathways using both the hypergeometric and the
GSEA approaches (Table 4 and Supplementary Table
S3). Both enrichment statistics identified several
oncogenes involved in pancreatic and prostate cancer
pathways, like CDC42 (associated to human miR-214),
EGFR (associated to human miR-134), RELA (associated
to miR-205), SMAD4 (associated to miR-200c),
CREB3L2 (associated to miR-187), ERBB4 (associated
to miR-31) and several other genes involved in the ErbB
and GnRH signaling pathways. ERBB2, ERBB4 and
EGFR have been implicated in the development of
many types of human cancer (50), while the
gonadotropin-releasing hormone (GnRH) receptor activa-
tion has been demonstrated to inhibit cell proliferation
in vitro and in vivo in prostate cancer (51–53) and
GnRH agonists have been used as therapeutical treatment
in prostate cancer clinical trials since the early 1980s (54).
Interestingly, only some of these interesting pathways
were found enriched using the list of targets obtained by
the GB annotation.
Among the miRNAs shared by both approaches, 20 out
of 32 are highly involved in prostate carcinogenesis [such
as miR-221, miR-222 (55,56) and miR-145 (57,58)], in
bladder cancer, [miR-23a, miR-23b and miR-205 (59)]
and in testis cancer [miR-373 (60)]. Among the
miRNAs identified only through the TB annotation,
Figure 5. Differences between gene and transcript-based annotation. Selected cases of correlations obtained between mRNA and miRNA with a
gene-based (black bars) and a transcript-based (red bars) annotation (only for genes with more than one 30UTR alternative transcript). The symbol
of the gene is reported at the top of the panel, the name of the miRNA targeting at least one transcript is reported in the x-axis and the numbers 1, 2
and 3 on the red bars represent the alternative transcripts of the same gene.
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29% (8 out of 28) are still cancer related, e.g. miR-106a
and miR-106b are known to be involved in prostate cancer
(58,61), miR-223 is involved in bladder cancer (59),
miR-200 in hepatocellular carcinoma (62), miR-15b in
chronic lymphocytic leukemia (63,64) and miR-17 in
lung cancer and lymphomas (65). Finally, among the
miRNAs identified using the GB annotation, only
miRNA (miR-184) has been reported to be involved in
prostate cancer development (58,66). These results
become even more intriguing if considering that correla-
tion and enrichment analyses have been performed on a
subset of all possible transcripts, i.e. those belonging to
genes with more than one alternative 30UTRs. This
suggests that the use of a GB annotation results in a sig-
nificant loss of information about post-transcriptional reg-
ulation, thus impairing the effectiveness of integrative
analyses in the identification of real miRNA targets.
CONCLUSIONS
The ENCODE consortium recently completed the charac-
terization of 1% of the human genome showing a striking
picture of its complex molecular activity. While the human
genome sequencing revealed a number of protein-coding
genes lower than previously estimated (<21 000, according
to ENSEMBL), ENCODE identified an extensive
transcriptional activity of the genome and highlighted
the complexity of the RNA transcriptome (67). At the
same time, the miRNA revolution in cell-biology and
functional genetics has deeply changed the scenario of
gene expression regulation, assigning an increasing impor-
tance to post-transcriptional mechanisms in development,
physiology and disease. Thus, in the light of these new
insights, the definition of gene should be somehow
revised (67). Recently Gerstein et al. (67) proposed an
alternative definition of gene as the ‘union of genomic
sequences encoding a coherent set of potentially
overlapping functional products’. This definition pays par-
ticular attention to 50 and 30 UTRs whose key roles in
translation, regulation, stability and localization of
mRNAs is widely accepted. Neglecting UTRs from the
definition of a gene, one can avoid the problem of
multiple 50 and 30 ends. Most of the longer protein-coding
transcripts identified by ENCODE, differ only in their
UTRs (67), thus reinforcing the Gerstein’s new suggested
definition of gene. This is particularly important when
studying post-transcriptional regulation, where the
30UTRs is the key region for a miRNA–mRNA seed
pairing.
Integrative approaches that aim at improving miRNA
target identification through the integration of miRNA
and mRNA expression profiles seem to underestimate
this problem. GB annotation (which ignores the issue of
alternative transcripts) is usually adopted to quantify
mRNA expression and to calculate miRNA–mRNA
expression correlation. Here, we evaluated the impact of
using a GB annotation approach rather than a more
appropriate TB one. Using prostate cancer as a case
study, we demonstrated how TB array annotation shows
more consistent results with the pathological state
investigated, even when limiting the analysis to genes
with multiple alternative transcripts. We identified a con-
siderable number of miRNA–mRNA interactions whose
GB anti-correlations show strong biases due to the
presence of alternative 30UTR transcripts with highly dif-
ferent expression profiles. Furthermore, the TB approach
was able to predict new putative miRNA–mRNA interac-
tions involving known oncogenes such as EGFR, RELA
and ERBB4 whose regulators, i.e. miR-134, miR-205 and
miR-31, respectively, could represent valid candidates for
further experimental validations. Unfortunately, the use
of a TB annotation lead to loss of information in
terms of filtered non-specific probes, thus reducing the
possibility of an exhaustive exploration of the
transcriptome regulation. In this perspective, alternative
technologies such as new generation deep-sequencers,
Affymetrix Exon Arrays or custom arrays, such as
Combimatrix, Agilent, Nimblegen (68), would provide a
wider coverage.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
Table 4. Enriched metabolic pathways of the GB and TB significantly anti-correlated miRNA–mRNA interac-
tions (using ENSEMBL and miRanda)
TB GB
Pathway P-value Pathway P-value
Pancreatic cancer 0.016 Wnt signaling pathway 0.05
Adherens junction 0.016 GnRH signaling pathway 0.1
Dorso-ventral axis formation 0.018 beta-Alanine metabolism 0.15
ErbB signaling pathway 0.024 MAPK signaling pathway 0.18
Neuroregulin receptor degredation protein-1
Controls ErbB3 receptor recycling
0.06
Regulation of actin cytoskeleton 0.07
Wnt signaling pathway 0.09
Adipocytokine signaling pathway 0.1
Prostate cancer 0.1
GnRH signaling pathway 0.1
Focal adhesion 0.1
Nucleic Acids Research, 2010 9
FUNDING
Funding for open access charges: Fondazione Cassa di
Risparmio di Padova e Rovigo (Progetti Eccellenza
2006, ‘A computational approach to the study of
skeletal muscle genomic expression in health and
disease’), University of Padova (CPDR070805 and
CPDA07591), MIUR (PRIN 2007Y84HTJ), University
of Modena (Finanziamento Linee Strategiche di
Sviluppo dell’Ateneo, Medicina Molecolare e
Rigenerativa, 2008) and Fondazione Cassa di Risparmio
di Modena (Bando ricerca, 2007).
Conflict of interest statement. None declared.
REFERENCES
1. Ambros,V. (2003) MicroRNA pathways in flies and worms:
growth, death, fat, stress, and timing. Cell, 113, 673–676.
2. Brennecke,J., Hipfner,D.R., Stark,A., Russell,R.B. and
Cohen,S.M. (2003) bantam encodes a developmentally regulated
microRNA that controls cell proliferation and regulates the
proapoptotic gene hid in Drosophila. Cell, 113, 25–36.
3. Lagos-Quintana,M., Rauhut,R., Lendeckel,W. and Tuschl,T.
(2001) Identification of novel genes coding for small expressed
RNAs. Science, 294, 853–858.
4. Lee,R.C., Feinbaum,R.L. and Ambros,V. (1993) The C. elegans
heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell, 75, 843–854.
5. Lim,L.P., Glasner,M.E., Yekta,S., Burge,C.B. and Bartel,D.P.
(2003) Vertebrate microRNA genes. Science, 299, 1540.
6. Palatnik,J.F., Allen,E., Wu,X., Schommer,C., Schwab,R.,
Carrington,J.C. and Weigel,D. (2003) Control of leaf
morphogenesis by microRNAs. Nature, 425, 257–263.
7. Pfeffer,S., Zavolan,M., Grasser,F.A., Chien,M., Russo,J.J., Ju,J.,
John,B., Enright,A.J., Marks,D., Sander,C. et al. (2004)
Identification of virus-encoded microRNAs. Science, 304,
734–736.
8. Reinhart,B.J., Slack,F.J., Basson,M., Pasquinelli,A.E.,
Bettinger,J.C., Rougvie,A.E., Horvitz,H.R. and Ruvkun,G. (2000)
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature, 403, 901–906.
9. Stefani,G. and Slack,F.J. (2008) Small non-coding RNAs in
animal development. Nat. Rev. Mol. Cell Biol., 9, 219–230.
10. Zhang,C. (2008) MicroRNomics: a newly emerging approach for
disease biology. Physiol. Genomics, 33, 139–147.
11. Blenkiron,C., Goldstein,L.D., Thorne,N.P., Spiteri,I., Chin,S.F.,
Dunning,M.J., Barbosa-Morais,N.L., Teschendorff,A.E.,
Green,A.R., Ellis,I.O. et al. (2007) MicroRNA expression
profiling of human breast cancer identifies new markers of tumor
subtype. Genome Biol., 8, R214.
12. Hobert,O. (2007) miRNAs play a tune. Cell, 131, 22–24.
13. Lu,J., Getz,G., Miska,E.A., Alvarez-Saavedra,E., Lamb,J.,
Peck,D., Sweet-Cordero,A., Ebert,B.L., Mak,R.H., Ferrando,A.A.
et al. (2005) MicroRNA expression profiles classify human
cancers. Nature, 435, 834–838.
14. Bartel,D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism,
and function. Cell, 116, 281–297.
15. Griffiths-Jones,S. (2004) The microRNA Registry. Nucleic Acids
Res, 32, D109–D111.
16. Bentwich,I. (2005) Prediction and validation of microRNAs and
their targets. FEBS Lett., 579, 5904–5910.
17. Gennarino,V.A., Sardiello,M., Avellino,R., Meola,N., Maselli,V.,
Anand,S., Cutillo,L., Ballabio,A. and Banfi,S. (2009) MicroRNA
target prediction by expression analysis of host genes.
Genome Res., 19, 481–90.
18. Griffiths-Jones,S., Saini,H.K., van Dongen,S. and Enright,A.J.
(2008) miRBase: tools for microRNA genomics. Nucleic Acids
Res., 36, D154–D158.
19. Krek,A., Grun,D., Poy,M.N., Wolf,R., Rosenberg,L.,
Epstein,E.J., MacMenamin,P., da Piedade,I., Gunsalus,K.C.,
Stoffel,M. et al. (2005) Combinatorial microRNA target
predictions. Nat. Genet., 37, 495–500.
20. John,B., Enright,A.J., Aravin,A., Tuschl,T., Sander,C. and
Marks,D.S. (2004) Human MicroRNA targets. PLoS Biol., 2,
e363.
21. Kertesz,M., Iovino,N., Unnerstall,U., Gaul,U. and Segal,E. (2007)
The role of site accessibility in microRNA target recognition.
Nat. Genet., 39, 1278–1284.
22. Kruger,J. and Rehmsmeier,M. (2006) RNAhybrid: microRNA
target prediction easy, fast and flexible. Nucleic Acids Res., 34,
W451–W454.
23. Kuhn,D.E., Martin,M.M., Feldman,D.S., Terry,A.V. Jr,
Nuovo,G.J. and Elton,T.S. (2008) Experimental validation of
miRNA targets. Methods, 44, 47–54.
24. Lewis,B.P., Shih,I.H., Jones-Rhoades,M.W., Bartel,D.P. and
Burge,C.B. (2003) Prediction of mammalian microRNA targets.
Cell, 115, 787–798.
25. Rajewsky,N. (2006) microRNA target predictions in animals.
Nat. Genet., 38(Suppl.), S8–S13.
26. Didiano,D. and Hobert,O. (2008) Molecular architecture of a
miRNA-regulated 30 UTR. Rna, 14, 1297–1317.
27. Grimson,A., Farh,K.K., Johnston,W.K., Garrett-Engele,P.,
Lim,L.P. and Bartel,D.P. (2007) MicroRNA targeting specificity
in mammals: determinants beyond seed pairing. Mol. Cell, 27,
91–105.
28. Hobert,O. (2008) Gene regulation by transcription factors and
microRNAs. Science, 319, 1785–1786.
29. Huang,J.C., Babak,T., Corson,T.W., Chua,G., Khan,S.,
Gallie,B.L., Hughes,T.R., Blencowe,B.J., Frey,B.J. and
Morris,Q.D. (2007) Using expression profiling data to identify
human microRNA targets. Nat. Methods, 4, 1045–1049.
30. Huang,J.C., Morris,Q.D. and Frey,B.J. (2007) Bayesian inference
of MicroRNA targets from sequence and expression data.
J. Comput. Biol., 14, 550–563.
31. Xin,F., Li,M., Balch,C., Thomson,M., Fan,M., Liu,Y.,
Hammond,S.M., Kim,S. and Nephew,K.P. (2009) Computational
analysis of microRNA profiles and their target genes suggests
significant involvement in breast cancer antiestrogen resistance.
Bioinformatics, 25, 430–434.
32. Wang,Y.P. and Li,K.B. (2009) Correlation of expression profiles
between microRNAs and mRNA targets using NCI-60 data.
BMC Genomics, 10, 218.
33. Ruike,Y., Ichimura,A., Tsuchiya,S., Shimizu,K., Kunimoto,R.,
Okuno,Y. and Tsujimoto,G. (2008) Global correlation analysis
for micro-RNA and mRNA expression profiles in human cell
lines. J. Hum. Genet., 53, 515–523.
34. Legendre,M., Ritchie,W., Lopez,F. and Gautheret,D. (2006)
Differential repression of alternative transcripts: a screen for
miRNA targets. PLoS Comput. Biol., 2, e43.
35. Thierry-Mieg,D. and Thierry-Mieg,J. (2006) AceView: a
comprehensive cDNA-supported gene and transcripts annotation.
Genome Biol., 7(Suppl. 1), S12 11–14.
36. Draghici,S., Khatri,P., Eklund,A.C. and Szallasi,Z. (2006)
Reliability and reproducibility issues in DNA microarray
measurements. Trends Genet., 22, 101–109.
37. Mecham,B.H., Klus,G.T., Strovel,J., Augustus,M., Byrne,D.,
Bozso,P., Wetmore,D.Z., Mariani,T.J., Kohane,I.S. and Szallasi,Z.
(2004) Sequence-matched probes produce increased cross-platform
consistency and more reproducible biological results in
microarray-based gene expression measurements. Nucleic Acids
Res., 32, e74.
38. Dai,M., Wang,P., Boyd,A.D., Kostov,G., Athey,B., Jones,E.G.,
Bunney,W.E., Myers,R.M., Speed,T.P., Akil,H. et al. (2005)
Evolving gene/transcript definitions significantly alter the
interpretation of GeneChip data. Nucleic Acids Res., 33, e175.
39. Ferrari,F., Bortoluzzi,S., Coppe,A., Sirota,A., Safran,M.,
Shmoish,M., Ferrari,S., Lancet,D., Danieli,G.A. and Bicciato,S.
(2007) Novel definition files for human GeneChips based on
GeneAnnot. BMC Bioinformatics, 8, 446.
40. Lu,J., Lee,J.C., Salit,M.L. and Cam,M.C. (2007) Transcript-based
redefinition of grouped oligonucleotide probe sets using AceView:
high-resolution annotation for microarrays. BMC Bioinformatics,
8, 108.
10 Nucleic Acids Research, 2010
41. Moll,A.G., Lindenmeyer,M.T., Kretzler,M., Nelson,P.J.,
Zimmer,R. and Cohen,C.D. (2009) Transcript-specific expression
profiles derived from sequence-based analysis of standard
microarrays. PLoS ONE, 4, e4702.
42. Lewis,B.P., Burge,C.B. and Bartel,D.P. (2005) Conserved seed
pairing, often flanked by adenosines, indicates that thousands of
human genes are microRNA targets. Cell, 120, 15–20.
43. Prueitt,R.L., Yi,M., Hudson,R.S., Wallace,T.A., Howe,T.M.,
Yfantis,H.G., Lee,D.H., Stephens,R.M., Liu,C.G., Calin,G.A.
et al. (2008) Expression of microRNAs and protein-coding genes
associated with perineural invasion in prostate cancer. Prostate,
68, 1152–1164.
44. Subramanian,A., Tamayo,P., Mootha,V.K., Mukherjee,S.,
Ebert,B.L., Gillette,M.A., Paulovich,A., Pomeroy,S.L.,
Golub,T.R., Lander,E.S. et al. (2005) Gene set enrichment
analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc. Natl Acad. Sci. USA, 102,
15545–15550.
45. Mootha,V.K., Lindgren,C.M., Eriksson,K.F., Subramanian,A.,
Sihag,S., Lehar,J., Puigserver,P., Carlsson,E., Ridderstrale,M.,
Laurila,E. et al. (2003) PGC-1alpha-responsive genes involved in
oxidative phosphorylation are coordinately downregulated in
human diabetes. Nat. Genet., 34, 267–273.
46. Huang da,W., Sherman,B.T. and Lempicki,R.A. (2009) Systematic
and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat. Protoc., 4, 44–57.
47. Kanehisa,M., Araki,M., Goto,S., Hattori,M., Hirakawa,M.,
Itoh,M., Katayama,T., Kawashima,S., Okuda,S., Tokimatsu,T.
et al. (2008) KEGG for linking genomes to life and the
environment. Nucleic Acids Res., 36, D480–D484.
48. Larsson,T.P., Murray,C.G., Hill,T., Fredriksson,R. and
Schioth,H.B. (2005) Comparison of the current RefSeq, Ensembl
and EST databases for counting genes and gene discovery.
FEBS Lett., 579, 690–698.
49. Okamura-Oho,Y., Miyashita,T. and Yamada,M. (2001)
Distinctive tissue distribution and phosphorylation of IRSp53
isoforms. Biochem. Biophys. Res. Commun., 289, 957–960.
50. Holbro,T. and Hynes,N.E. (2004) ErbB receptors: directing key
signaling networks throughout life. Annu. Rev. Pharmacol.
Toxicol., 44, 195–217.
51. Bahk,J.Y., Hyun,J.S., Lee,H., Kim,M.O., Cho,G.J., Lee,B.H. and
Choi,W.S. (1998) Expression of gonadotropin-releasing hormone
(GnRH) and GnRH receptor mRNA in prostate cancer cells and
effect of GnRH on the proliferation of prostate cancer cells. Urol.
Res., 26, 259–264.
52. Dondi,D., Limonta,P., Moretti,R.M., Marelli,M.M., Garattini,E.
and Motta,M. (1994) Antiproliferative effects of luteinizing
hormone-releasing hormone (LHRH) agonists on human
androgen-independent prostate cancer cell line DU 145: evidence
for an autocrine-inhibitory LHRH loop. Cancer Res., 54,
4091–4095.
53. Halmos,G., Arencibia,J.M., Schally,A.V., Davis,R. and
Bostwick,D.G. (2000) High incidence of receptors for luteinizing
hormone-releasing hormone (LHRH) and LHRH receptor gene
expression in human prostate cancers. J. Urol., 163, 623–629.
54. Tolis,G., Ackman,D., Stellos,A., Mehta,A., Labrie,F.,
Fazekas,A.T., Comaru-Schally,A.M. and Schally,A.V. (1982)
Tumor growth inhibition in patients with prostatic carcinoma
treated with luteinizing hormone-releasing hormone agonists.
Proc. Natl Acad. Sci. USA, 79, 1658–1662.
55. Shi,X.B., Tepper,C.G. and White,R.W. (2008) MicroRNAs and
prostate cancer. J. Cell Mol. Med., 12, 1456–1465.
56. Galardi,S., Mercatelli,N., Giorda,E., Massalini,S., Frajese,G.V.,
Ciafre,S.A. and Farace,M.G. (2007) miR-221 and miR-222
expression affects the proliferation potential of human prostate
carcinoma cell lines by targeting p27Kip1. J. Biol. Chem., 282,
23716–23724.
57. Ozen,M., Creighton,C.J., Ozdemir,M. and Ittmann,M. (2008)
Widespread deregulation of microRNA expression in human
prostate cancer. Oncogene, 27, 1788–1793.
58. Schaefer,A., Jung,M., Kristiansen,G., Lein,M., Schrader,M.,
Miller,K., Stephan,C. and Jung,K. (2008) MicroRNAs and
cancer: Current state and future perspectives in urologic
oncology. Urol. Oncol., Dec 29 [Epub ahead of print].
59. Gottardo,F., Liu,C.G., Ferracin,M., Calin,G.A., Fassan,M.,
Bassi,P., Sevignani,C., Byrne,D., Negrini,M., Pagano,F. et al.
(2007) Micro-RNA profiling in kidney and bladder cancers.
Urol. Oncol., 25, 387–392.
60. Voorhoeve,P.M., le Sage,C., Schrier,M., Gillis,A.J., Stoop,H.,
Nagel,R., Liu,Y.P., van Duijse,J., Drost,J., Griekspoor,A. et al.
(2007) A genetic screen implicates miRNA-372 and miRNA-373
as oncogenes in testicular germ cell tumors. Adv. Exp. Med. Biol.,
604, 17–46.
61. Ambs,S., Prueitt,R.L., Yi,M., Hudson,R.S., Howe,T.M.,
Petrocca,F., Wallace,T.A., Liu,C.G., Volinia,S., Calin,G.A. et al.
(2008) Genomic profiling of microRNA and messenger RNA
reveals deregulated microRNA expression in prostate cancer.
Cancer Res., 68, 6162–6170.
62. Murakami,Y., Yasuda,T., Saigo,K., Urashima,T., Toyoda,H.,
Okanoue,T. and Shimotohno,K. (2006) Comprehensive analysis of
microRNA expression patterns in hepatocellular carcinoma and
non-tumorous tissues. Oncogene, 25, 2537–2545.
63. Calin,G.A., Ferracin,M., Cimmino,A., Di Leva,G., Shimizu,M.,
Wojcik,S.E., Iorio,M.V., Visone,R., Sever,N.I., Fabbri,M. et al.
(2005) A MicroRNA signature associated with prognosis and
progression in chronic lymphocytic leukemia. N. Engl. J. Med.,
353, 1793–1801.
64. Cimmino,A., Calin,G.A., Fabbri,M., Iorio,M.V., Ferracin,M.,
Shimizu,M., Wojcik,S.E., Aqeilan,R.I., Zupo,S., Dono,M. et al.
(2005) miR-15 and miR-16 induce apoptosis by targeting BCL2.
Proc. Natl Acad. Sci. USA, 102, 13944–13949.
65. Zhang,B., Pan,X., Cobb,G.P. and Anderson,T.A. (2007)
microRNAs as oncogenes and tumor suppressors. Dev. Biol., 302,
1–12.
66. Lin,S.L., Chiang,A., Chang,D. and Ying,S.Y. (2008) Loss of
mir-146a function in hormone-refractory prostate cancer. Rna, 14,
417–424.
67. Gerstein,M.B., Bruce,C., Rozowsky,J.S., Zheng,D., Du,J.,
Korbel,J.O., Emanuelsson,O., Zhang,Z.D., Weissman,S. and
Snyder,M. (2007) What is a gene, post-ENCODE? History and
updated definition. Genome Res., 17, 669–681.
68. Ghindilis,A.L., Smith,M.W., Schwarzkopf,K.R., Roth,K.M.,
Peyvan,K., Munro,S.B., Lodes,M.J., Stover,A.G., Bernards,K.,
Dill,K. et al. (2007) CombiMatrix oligonucleotide arrays:
genotyping and gene expression assays employing electrochemical
detection. Biosens. Bioelectron., 22, 1853–1860.
Nucleic Acids Research, 2010 11
